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Perioperative renal failure in pediatric heart
transplant recipients: Outcome and risk
factors
Pediatric heart transplantation is a well-accepted
treatment for children with end-stage heart
disease, including cardiomyopathies, failed palli-
ation of complex congenital heart defects, and
congenital heart defects for which no eﬀective
palliation is currently available (1, 2). Approxi-
mately 300–400 pediatric heart transplants are
performed each year in the United States. Out-
comes are continually improving, with one-yr
survival above 90% and ﬁve-yr survival above
78% (1, 2).
PRF, deﬁned as requiring dialysis during the
period from transplant listing to discharge from
the transplant hospitalization, is experienced by
11–15% of adult heart transplant recipients. The
outcome in this group is poor, with 40% mor-
tality before hospital discharge, more than 10
times that of recipients without PRF (3, 4). Risk
factors for PRF in this group include older age of
the recipient, hypertrophic cardiomyopathy diag-
nosis, the need for pretransplant ventricular
assist device support, and longer donor ischemia
time (5–7).
Infants and children waiting for a donor heart
may have varying degrees of renal impairment,
with some requiring dialysis (8, 9). In one single
center study, 39 of 308 (12.6%) transplant
recipients met the deﬁnition of PRF. The one,
two, and ﬁve-yr survival in the PRF group was
signiﬁcantly lower than that in the No-PRF
group (9). Speciﬁc risk factors for developing
PRF have not been identiﬁed in the pediatric
heart transplant population.
The UNOS database is a multi-institutional
resource that allows questions about uncommon
complications in heart transplant recipients to be
studied. The purpose of this study is to deﬁne the
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Abstract: PRF is encountered in 10–13% of adult heart transplants.
Only one study of a single centers experience with PRF has been
reported in pediatric patients. This study examines the eﬀect of PRF on
pediatric heart transplant outcome using the UNOS database. A total
of 3598 patients met inclusion criteria, of whom 254 (7%) had PRF.
The PRF group comprised 31 recipients requiring PRE and 223
recipients requiring POST. Compared with No-PRF patients, PRE
patients had similar survival rate and POST patients had decreased
survival rate at 30 days, one, ﬁve, and 10-yr post-transplant
(p < 0.001). PRF patients also had signiﬁcantly lower graft survival at
one, ﬁve, and 10 yr (p < 0.001). Risk factors for developing PRF in-
cluded ECMO, ventilator, and inotropic support at listing and CHD as
the listing diagnosis. PRF increased the duration of hospital stay and
the incidence of chronic severe renal dysfunction. PRF that requires
POST (whether or not it began pretransplant) has a signiﬁcant negative
impact on pediatric heart transplant outcome. Speciﬁc characteristics
identify patients at particular high risk of developing PRF.
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prevalence of PRF in pediatric cardiac transplant
recipients and determine its impact on heart
transplant outcome. A secondary goal of this
study is to identify risk factors for developing PRF
inanationalpediatricheart transplantpopulation.
Methods
We obtained national transplant data collected by the
OPTN and maintained by the SRTR. OPTN has prospec-
tively collected data on all candidates for and recipients of
solid-organ transplants in the US since 1988. Data are
submitted at the time of listing, at transplantation. Follow
up data are collected during yearly follow up, and when
signiﬁcant events occur (rejection, graft failure, death, etc.).
Each center must submit a yearly report for each patient
that includes graft function, coronary disease, and renal
function. Since 1993, the presence or absence of peri-oper-
ative renal failure, deﬁned as requiring dialysis during the
period from transplant listing to discharge from the trans-
plant hospitalization, has been included in the registry.
We obtained data for all recipients £ 18 yr of age listed
for heart transplant who received a ﬁrst organ between 1993
and 2008. Recipients with missing perioperative renal status
and patients listed for heart transplantation who died
waiting were excluded. In the UNOS/OPTN database,
anonymity of patient information is maintained by coding
of data during compilation, so our Institutional Review
Board granted waiver of consent.
Patients were divided into two groups: (i) those with PRF
and (ii) those without PRF (No-PRF). Continuous vari-
ables are summarized by mean ± s.d. Categorical variables
are shown as frequencies and percentages. Demographic
data such as age, weight, height, gender, race, and diagnosis
requiring transplant were compared between groups using
Students T-test, Fishers exact test or chi-square test as
appropriate.
Kaplan–Meier survival analysis was used to estimate one,
ﬁve, and 10-yr recipient and graft survival. The impact of
PRF on patient and graft survival was assessed using the
stratiﬁed log-rank test. To control for illness severity, we
performed the stratiﬁed log-rank test for recipients who
were on ECMO support, ventilator support, and inotropic
support at the time of listing. Cox proportional hazard
models were used to assess risk factors for death in the PRF
group. Demographic and clinical variables (medical condi-
tion, primary diagnosis, ventilator support, ECMO support,
and inotropic support) were considered. Proportional-haz-
ards assumptions were veriﬁed by assessing time-dependent
covariates. Risk factors associated with developing PRF
were explored in univariate and multivariate logistic
regression analyses from which odds ratios and 95%
conﬁdence intervals were generated. Variables that were
signiﬁcant at the 0.1 level in univariate analyses were
included in a stepwise multivariate logistic regression
model. Outcomes including length of hospital stay, episodes
of rejection, important infections, CAD, severe renal
dysfunction, and hypertension were compared between the
two groups using Students T-test, Fishers exact test or
chi-square test as appropriate.
Results
A total of 3712 primary pediatric cardiac trans-
plants were performed between 1993 and 2008, of
which 3598 patients had adequate data to be
included and 114 recipients were excluded
because of incomplete data. Seven percent (254/
3598) met the deﬁnition for PRF. The prevalence
of PRF was similar across transplant eras: 1993–
1998, 7.3%; 1998–2003, 6.9%; 2003–2008, 7.2%.
The PRF group comprised 254 recipients. There
were 78 recipients who required PRE, of whom
47 also required POST. And there were 176
recipients required only POST.
Demographic parameters
As shown in Table 1, there was no diﬀerence
between groups in age and age group. CHD was
the most common primary diagnosis leading to
listing for transplant in the PRF group, cardio-
myopathy was the most common one in the
No-PRF group. The PRF group had more
Caucasian recipients than the No-PRF group.
There were no signiﬁcant diﬀerences between
groups in weight, height, or gender.
Post-transplant patient and graft survival
Of the transplanted patients, 93.3% patients
survived to 30 days post-transplant. There was
a signiﬁcantly lower 30-day survival in the PRF
group, compared with No-PRF group (72% vs.
95%; p < 0.001). As shown in Table 2, causes of
death were similar in the PRF and No-PRF
group. Early mortality data were stratiﬁed into
three eras: 1993–1998; 1998–2003; and 2003–2008.
Table 1. Clinical and demographic characteristics
PRF (n = 254) No-PRF (n = 3344) p Value
Age (yr)
Mean + s.d. 6.4 (6.2) 6.2 (6.1) 0.6
Median (25th–75th) 5 (0–12) 4 (0–13)
Age group (%)
<1 yr 85 (33) 993 (30) 0.5
1–10 yr 117 (46) 1551 (46)
>10 yr 52 (20) 802 (24)
Weight (kg) 24.6 (24.7) 25.1 (24.0) 0.74
Height (cm) 104 (46) 106 (45) 0.42
Gender (%)
M 146 (43) 1886 (56) 0.74
F 108 (57) 1458 (43)
Race (%)
Caucasian 176 (69) 2051 (61) 0.001*
Black 36 (14) 634 (19)
Hispanic 25 (10) 472 (14)
Other 17 (7) 187 (6)
Diagnosis (%)
CHD 157 (62) 1456 (44) <0.001*
Cardiomyopathy 97 (38) 1888 (56)
Clinical and demographic characteristics compared between the PRF group and
No-PRF group. Asterisk denotes statistically significant difference.
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Early mortality in the No-PRF group decreased
signiﬁcantly with later era (p < 0.05) and did
decline over the transplant era. In the PRF
group, however, the decrease did not reach
statistical signiﬁcance.
The one, ﬁve, and 10-yr patient survival rate
was 45%, 41%, and 40% in the PRF group,
signiﬁcantly below the No-PRF group (89%,
79%, and 75%; all p < 0.001) (Fig. 1). When
survival was made conditional upon surviving
to six months post-transplant, the diﬀerence
between the PRF and No-PRF groups became
insigniﬁcant, as shown in Fig. 2. The diﬀerence
in survival between groups was therefore
accounted for predominantly by early mortal-
ity.
PRF recipients were divided into three groups
based upon when dialysis was required: PRE
only, BOTH, and POST only. Patients survival
for each group was as follows: one yr (97% vs.
38% vs. 38%; p < 0.001), ﬁve yr (90% vs. 28%
Table 2. Causes of death within 30 days post-transplant
PRF (n = 70) No-PRF (n = 170) p Value
Graft failure (%) 21 (30) 70 (40) NS
Infection (%) 15 (21) 13 (8) NS
Multi-organ failure (%) 18 (26) 0 (0) NS
Cardiovascular disease (%) 6 (9) 25 (15) NS
Others (%) 0 62 (36) NS
Cause of death within 30 days post-transplant compared between PRF group
and No-PRF group. There were no significant differences between the groups.
Fig. 1. Patient survival as a
function of time post-transplant,
stratiﬁed by presence or absence
of PRF. Survival was signiﬁ-
cantly lower in the PRF than in
the No-PRF group (p < 0.001).
Fig. 2. Post-transplant patient survival, conditional on survival to six months, stratiﬁed by presence or absence of PRF. The
survival in the PRF and No-PRF group was not signiﬁcant diﬀerent (p = 0.25).
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vs. 36%; p < 0.001), and 10 yr post-transplant
(84% vs. 28% vs. 35%; p < 0.001). For recip-
ients requiring dialysis only pretransplant, sur-
vival is similar to the No-PRF group (p = 0.88).
The one, ﬁve and 10-yr graft survival was
43%, 38%, and 37% in the PRF group, signif-
icantly below the No-PRF group (88%, 79%,
and 72%), all p < 0.001 (Fig. 3). The one, ﬁve
and 10-yr graft survival was 95%, 80%, and 74%
in the PRE group, signiﬁcantly above the BOTH
group (42%, 29%, and 27%; all p < 0.001) and
POST group (38%, 34%, and 32%; all
p < 0.01). For recipients only requiring dialysis
pretransplant, graft survival at each interval is
similar to the No-PRF group (p = 0.88).
Independent predictors of death for patients in
the PRF group are summarized in Table 3 and
include requiring POST, primary diagnosis of
CHD, and being of Hispanic ethnicity. Com-
pared with being in the adolescent group, being
in the infant group is a predictor of mortality.
Weight, waiting time, requiring ventilator, ino-
tropic or ECMO support at listing, admission to
an ICU pretransplant were not risk factors for
mortality in the PRF group.
Morbidity during transplant hospitalization
Transplant hospitalization morbidity is summa-
rized in Table 4. The length of hospital stay post-
transplant was signiﬁcantly longer in the PRF
group than in the No-PRF group. The PRF
group experienced more cardiac re-operations,
permanent pacemaker implants, signiﬁcant infec-
tions requiring treatment, and stroke than the
No-PRF group. There was no diﬀerence between
groups in the number of rejection episodes before
hospital discharge.
Morbidity after hospital discharge
Table 5 summarizes morbidity at one, ﬁve, and
seven yr post-transplant. Renal dysfunction was
Fig. 3. Graft survival as a function of time post-transplant, stratiﬁed by presence or absence of PRF. Survival was signiﬁ-
cantly lower in the PRF than in the No-PRF group (p < 0.001).
Table 3. Risk factors associated with overall mortality in the PRF group
Variables Hazard ratio (95% CI) p Value
Univariate
Serum creatinine level, mg/dL 1.11 (1.01–1.2) <0.026*
CHD 2.2 (1.5–3.1) <0.0001*
Race (Hispanic vs. Caucasian) 0.5 (0.27–0.95) 0.03*
POST 6.0 (3.2–8.7) 0.001*
Multivariate
CHD 2.1 (1.5–3.1) <0.0001*
Race (Caucasian vs. Hispanic) 0.5 (0.27–0.95) 0.031*
POST 5.8 (3.3–9.6) 0.001*
Univariate and multivariate risk factors associated with overall mortality in the
PRF group using Cox Regression model. CHD represents CHD vs. non-CHD.
Asterisk denotes significant difference between groups.
Table 4. Morbidities during transplant hospitalization
Parameter
PRF group
(n = 254)
No-PRF group
(n = 3344) p Value
Length of hospital stay
(mean € s.d.)
43 € 38 24 € 40 <0.001
Number of acute rejection
episode (mean € s.d.)
0.82 € 1.3 0.8 € 1.3 0.8
Cardiac re-operation (%) 63 (26) 191 (6.3) <0.001
Pacemaker implantation (%) 9 (3.5) 36 (1) 0.003
Infection (%) 153 (65) 697 (23) <0.001
Stroke (%) 23 (9) 70 (2) <0.001
Morbidity during transplant hospitalization compared between the PRF and
No-PRF groups.
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more common in the PRF group than in the
No-PRF one-yr post-transplant (p < 0.001), but
this diﬀerence did not persist at ﬁve and seven yr
post-transplant. Severe renal dysfunction, deﬁned
as requiring chronic dialysis, renal transplant or
with a serum creatinine concentration above
2.5 mg/dL, was signiﬁcantly more prevalent in
the PRF group than in the No-PRF at one-yr
post-transplant. As with renal dysfunction, the
diﬀerence in incidence of severe renal dysfunction
did not persist at ﬁve and seven yr. Of recipients
in the PRF group, nine died within ﬁve yr
post-transplant and the other three recipients
recovered their renal function. Twenty-six (1%)
recipients in the No-PRF group had severe renal
dysfunction at one yr post-transplant, of whom
15 died within ﬁve yr, six recovered renal
function, and ﬁve persisted with renal dysfunc-
tion at most recent follow up. The prevalence of
diabetes and hypertension was higher in the
PRF group than in the No-PRF group only
at seven yr post-transplant (p = 0.003 and
p = 0.04). The incidence of CAD, the number
of rejection episodes and infections requiring
hospitalization did not diﬀer between the
PRF and No-PRF groups at any time post-
transplant.
Risk factors associated with PRF
Univariate analysis of variables identiﬁed seven
signiﬁcant risk factors for developing PRF as
shown in Table 6. Risk factors included requir-
ing ECMO, ventilator, or inotropic support at
listing, having an infection requiring intravenous
drug therapy within two wk prior to listing,
CHD as the listing diagnosis, ICU admission vs.
being home at the time of listing. In multivariate
analysis, risk factors that remained signiﬁcant
included requiring ECMO and ventilator sup-
port, primary diagnosis of CHD and ICU stay at
the time of listing for transplant.
Discussion
This study represents the largest analysis of PRF
in the pediatric heart transplant experience. There
is a paucity of data on the impact of PRF on
transplant outcomes from any single institution
because of the rarity of heart transplantation in
children. To overcome this limitation, the
UNOS/OPTN registry was used to assess out-
come in primary heart transplant recipients. Our
study found that the prevalence of PRF was 7%
Table 5. Morbidity after hospital discharge one-yr post-transplant
1-yr post 5-yr post 7-yr post
PRF
n = 113
No-PRF
n = 2821
PRF
n = 43
No-PRF
n = 1458
PRF
n = 36
No-PRF
n = 1008
Rejection* 1.8 1.75 0.08 0.04 0.08 0.04
CAD (%) 0 (0) 26 (0.9) 1 (2) 95 (6) 1 (3) 85 (8)
Renal dysfunction (%) 23 (20) 118 (4) 4 (8) 117 (9) 6 (17) 87 (9)
Severe renal dysfunction (%) 12 (11) 26 (0.9) 1 (2.3) 14 (1) 2 (5.5) 19 (2)
Chronic dialysis 7 9 1 5 1 7
Serum creatinine >2.5 12 25 1 14 2 17
Renal transplant 2 0 1 1 0 2
Infection (%) 41 (36) 711 (25) 7 (16) 172 (12) 5 (14) 91 (9)
Diabetes (%) 3 (3) 55 (2) 1 (2) 35 (4) 4 (12) 23 (2)
Hypertension (%) 32 (28) 588 (20) 20 (47) 506 (35) 19 (57) 344 (37)
Mean episode of rejection, infection-requiring hospitalization, incidence of CAD, renal dysfunction, diabetes, and hypertension compared between PRF and No-PRF
group at one, five, and seven yr post-transplant.
*Mean episode of rejection.
Number and percentage of coronary artery disease.
Table 6. Risk factors for developing PRF
Variables Relative risk (95% CI) p Value
Univariate
ECMO support (Y) 5.9 (3.9–7.9) <0.0001
Ventilator support (Y) 2.6 (2.0–3.5) <0.0001
Infection* 2.3 (1.5–3.6) 0.0027
CHD* 2.1 (1.6–2.7) 0.003
Medical condition (ICU vs. home) 2.1 (1.5–2.9) <0.0001
Inotrope support (Y) 1.6 (1.2–2.1) <0.0001
Multivariate
ECMO support (Y) 3.1 (2.04.9) <0.0001
Ventilator support (Y) 1.9 (1.3–2.7) 0.0006
CHD* 2.1 (21.5–2.8) <0.0001
Medical condition (ICU vs. home) 1.1 (1.1–2.4) <0.0001
Pretransplant risk factors for developing PRF obtained by univaraite and
multivariate regression models. Infection (*) represents significant infection
requiring intravenous treatment two wk prior to listing. Medical condition
represents recipient stay in ICU as opposed to home at the time of listing.
ECMO, ventilator, or inotrope support refer to support at the time of listing.
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in pediatric primary heart transplants performed
between 1993 and 2008. Post-transplant patient
survival was only compromised in patients who
required dialysis post-transplant (whether or not
it began pretransplant. PRE need only did not
impact short- and long-term outcomes. When
patient survival was made conditional upon
surviving to six months post-transplant, the
diﬀerence between the PRF and No-PRF groups
became insigniﬁcant. In our study, requiring
POST, a primary diagnosis of CHD and being of
Hispanic ethnicity were independent predictors
of mortality in the PRF group.
PRF is experienced by 11–15% of adult heart
transplant recipients (5), and is a major determi-
nant of one-yr survival and subsequent chronic
renal failure (4–8). Information on PRF in
pediatric heart transplant recipients is limited.
A single center study reported that 12.6% of 308
pediatric transplant recipients developed PRF,
and had lower one and ﬁve-yr survival than
No-PRF patients (10).
The present report has advantages over single
center reports in that it captures data from all
children who received a heart transplant in the
United States, increasing statistical power to
identify several important national trends. Spe-
ciﬁcally, it is the ﬁrst study to our knowledge that
deﬁnes the prevalence of PRF in pediatric
cardiac transplant recipients, determines its
impact on heart transplant outcome and identi-
ﬁes risk factors associated with developing PRF.
We found a lower prevalence of PRF (7%) than
the adult study (5), likely because pediatric
recipients generally have a lower incidence of
comorbidities than adults. We also found a better
post-transplant survival than that reported from
a single pediatric transplant center (10), likely
because death of a few patients from a single
center study will skew outcome data negatively.
PRF is a well-known complication after car-
diopulmonary bypass. The incidence of PRF in
children with normal kidney function undergoing
open heart surgery is reported to range from 2%
to 11% (11–13). The incidence increased to 25%
in children with solitary functioning kidney (14).
Requiring renal placement therapy post-heart
surgery carries as high as 40–80% of mortality
(14, 15). Our study found that the incidence of
PRF and mortality in pediatric heart transplant
recipients were similar to children undergoing
non-transplant open heart surgery.
Compared with transplant recipients with a
primary diagnosis of cardiomyopathy, those with
a primary diagnosis of CHD are at increased risk
for developing PRF. The most signiﬁcant impact
of PRF on survival of pediatric cardiac transplant
is seen during the ﬁrst six months after surgery.
There is huge diﬀerence in post-transplant
patient survival between PRE and POST groups.
The one, ﬁve and 10-yr graft survival is 95%,
80%, and 74% in the PRE group, signiﬁcantly
above POST group (38%, 34%, and 32%; all
p < 0.01). An explanation for this could be that
PRE is most likely secondary to heart failure and
improvement of cardiac function post-transplant
provides an opportunity to recover renal func-
tion. By contrast, PRF that included the need for
dialysis post-transplant had negative impact on
survival. This may relate to poor graft function
on other comorbidity that produces permanent
renal dysfunction.
In our study, 40% of recipients requiring PRE
did not require POST and they had an excellent
outcome, which suggests that patients needing
dialysis while awaiting a heart transplant should
be considered suitable heart transplant candi-
dates.
The risk factors associated with developing
PRF identiﬁed in our study can be applied
clinically. For these high-risk patients, it is
particularly important to avoid nephrotoxic
agents while awaiting heart transplant, to opti-
mize peri-operative hemodynamic status to pre-
vent prolonged low cardiac output and multiple
organ failure. Strategies to optimize hemody-
namics include carefully maintain euvolemia,
judicious use of inotropic support, prophylactic
administration of renal protection strategies such
as dopamine infusion, and consideration of
mechanical support.
Limitations
This is a multi-institutional retrospective data-
base study which limits the strengths of conclu-
sions derived by pooling institutional experiences
that have diﬀerent treatment protocols for their
patients both pre- and post-transplant. This
database does not allow us to assess the eﬀect
of type of CHD (HLHS, single ventricle, and two
ventricle), prior heart surgery (failed palliation
and rescue transplant surgery), or duration of
renal replacement support on outcomes. We were
not able to take into account the immunosup-
pressive regimen on renal dysfunction because of
database limitations. There are only 254 patients
in the PRF group. Such a small number of
patients do not allow us to identify black race as
a risk factor for mortality or examine the
additive eﬀect of risk factors such as combined
CHD and ECMO or ventilator support.
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